ArticleScience translational medicine2020
Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 88 citations in OpenAlex.
- Glycosaminoglycans in tissue regeneration: Insights into glycobiology and their biomedical application.Bioactive materials · 2026Review
- A one-step chemical derivatization strategy for mass spectrometric characterization of synthetic mimetics of sulfated glycosaminoglycans.Analytical methods : advancing methods and applications · 2026Article
- Deciphering Age-Dependent ECM Remodelling in Liver: Proteomic Profiling and Its Implications for Aging and Therapeutic Targets.Cell proliferation · 2025Article
- Exploring mechanisms of radiation-induced myocardial fibrosis using HMGB1 neutralizing antibody.Journal of molecular histology · 2025Article
- CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.Acta pharmaceutica Sinica. B · 2025Article
- A transformer-based strategy to develop RP20 as a potent RIPK2 inhibitor for acetaminophen-induced acute liver injury.Acta pharmaceutica Sinica. B · 2025Article
- Unraveling the microbial diversity of bovine liver abscesses: isolation, identification, and genomic characterization of theMicrobiology spectrum · 2025Article
- Restoring Tumor Cell Immunogenicity Through Ion-Assisted p53 mRNA Domestication for Enhanced In Situ Cancer Vaccination Effect.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- UtilizingAmerican journal of physiology. Cell physiology · 2025Review
- Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure.Nature communications · 2025Article
- Analysis of the prognostic efficacy of syndecan-1 for patients with ACLF and its functional role in liver regeneration.BMC medicine · 2025Article
- Emerging Roles of High-mobility Group Box-1 in Liver Disease.Journal of clinical and translational hepatology · 2024Review
- Syndecan-1: a key player in health and disease.Immunogenetics · 2024Review
- Selectively targeting the AdipoR2-CaM-CaMKII-NOS3 axis by SCM-198 as a rapid-acting therapy for advanced acute liver failure.Nature communications · 2024Article
- Post-COVID Mucormycosis-Conceptual Etiology and New Treatment Options.Journal of maxillofacial and oral surgery · 2024Article
- The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.Biomolecules · 2024Review
- HMGB1 as an extracellular pro-inflammatory cytokine: Implications for drug-induced organic damage.Cell biology and toxicology · 2024Review
- Tailor-Made Polysaccharides for Biomedical Applications.ACS applied bio materials · 2024Review
- Glycosaminoglycan microarrays for studying glycosaminoglycan-protein systems.Carbohydrate polymers · 2024Review
- Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Katelyn ArnoldDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-1750-1253
Yongmei XuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-3756-581X
Erica M SparkenbaughDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-5529-7847
Miaomiao LiDepartment of Oral Biology, School of Dental Medicine, State University of New York at Buffalo, Buffalo, NY 14214, USA.
Xiaorui HanDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0001-9510-4838
Xing ZhangDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Ke XiaDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0001-9699-9901
Mark PiegoreDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-8305-5968
Fuming ZhangDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0003-2803-3704
Xiaoxiao ZhangDepartment of Oral Biology, School of Dental Medicine, State University of New York at Buffalo, Buffalo, NY 14214, USA.
Mike HendersonDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Vijayakanth PagadalaGlycan Therapeutics, LLC, Raleigh, NC 27606, USA.ORCID 0000-0001-7349-4230
Guowei SuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0003-2668-9275
Lisi TanDepartment of Oral Biology, School of Dental Medicine, State University of New York at Buffalo, Buffalo, NY 14214, USA.
Pyong Woo ParkDivision of Respiratory Diseases, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Richard T StravitzHume-Lee Transplant Center of Virginia Commonwealth University, Richmond, VA 23219, USA.
Nigel S KeyDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Robert J LinhardtDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0003-2219-5833
Rafal PawlinskiDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5162-7135
Ding XuDepartment of Oral Biology, School of Dental Medicine, State University of New York at Buffalo, Buffalo, NY 14214, USA. jian_liu@unc.edu dingxu@buffalo.edu.ORCID 0000-0001-9380-2712
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA. jian_liu@unc.edu dingxu@buffalo.edu.ORCID 0000-0001-8552-1400
University of North Carolina at Chapel Hill · USRensselaer Polytechnic Institute · USUniversity at Buffalo, State University of New York · USBoston Children's Hospital · USG1 Therapeutics (United States) · USVirginia Commonwealth University · US
Funding
UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian Michael Carroll · 1999 to 2026
$31.6MIn vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2MDevelopment of dekaparin to replace animal-sourced heparinR44HL139187 · NHLBI · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2025
$4.2MEndothelial glycocalyx reconstitution during sepsisR01HL125371 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI LINHARDT, ROBERT J, SCHMIDT, ERIC PETER · 2014 to 2018
$3.4MDiverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating GlycosaminoglycansR44GM134738 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2021
$3.2MThe role ofglycosaminoglycan N-sulfation in glomerular biology/pathobiologyR01DK111958 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI MCCARTHY, KEVIN JOHN · 2017 to 2021
$2.6MReactor for Insect Cell CultureR42GM128484 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI XU, YONGMEI · 2018 to 2020
$1.9MHeparan Sulfate–Osteoprotegerin Interactions in Bone RemodelingR01AR070179 · NIAMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XU, DING · 2017 to 2021
$1.7MMechanisms of coagulation-dependent pathologies in sickle cell diseaseR01HL142604 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAWLINSKI, RAFAL L · 2018 to 2021
$1.6MUncovering the controlling mechanisms in heparan sulfate biosynthesisU01GM102137 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2013 to 2016
$1.2MSynthesis and Pharmacological Evaluation of Homogenous Ultra-Low Molecular Weight HeparinsR01HL144970 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2019 to 2021
$946kDeveloping Heparan Sulfate Glycan ArrayR41GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI LIU, JIAN · 2017 to 2018
$297kNHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL125371NHLBI NIH HHS R01 HL142604NHLBI NIH HHS R01 HL144970NHLBI NIH HHS R41 HL139187NHLBI NIH HHS R44 HL139187NIAMS NIH HHS R01 AR070179NIDDK NIH HHS P30 DK056350NIDDK NIH HHS R01 DK111958NIGMS NIH HHS R41 GM123792NIGMS NIH HHS R42 GM128484NIGMS NIH HHS R44 GM134738NIGMS NIH HHS U01 GM102137
Abstract
Acetaminophen/paracetamol (APAP) overdose is the leading cause of drug-induced acute liver failure (ALF) in the United States and Europe. The progression of the disease is attributed to sterile inflammation induced by the release of high mobility group box 1 (HMGB1) and the interaction with receptor for advanced glycation end products (RAGE). A specific, effective, and safe approach to neutralize the proinflammatory activity of HMGB1 is highly desirable. Here, we found that a heparan sulfate (HS) octadecasaccharide (18-mer-HP or hepatoprotective 18-mer) displays potent hepatoprotection by targeting the HMGB1/RAGE axis. Endogenous HS proteoglycan, syndecan-1, is shed in response to APAP overdose in mice and humans. Furthermore, purified syndecan-1, but not syndecan-1 core protein, binds to HMGB1, suggesting that HMGB1 binds to HS polysaccharide side chains of syndecan-1. Last, we compared the protection effect between 18-mer-HP and
Indexed as
Chemical and Drug Induced Liver InjuryLiver Failure, AcuteAcetaminophenAnimalsAnti-Inflammatory AgentsEuropeHeparan SulfateHumansLiverMiceMice, Inbred C57BLAcetaminophenAnti-Inflammatory AgentsHeparan Sulfate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.